المؤلفون: Iorio, Francesco, Knijnenburg, Theo A., Vis, Daniel J., Bignell, Graham, Menden, Michael P., Schubert, Michael, Aben, Nanne, Gonçalves, Emanuel, Barthorpe, Syd, Lightfoot, Howard, Cokelae, Thomas, Greninger, Patricia, Dyk, Ewald van, Chang, Han, Silva, Heshani de, Heyn, Holger, Deng, Xianming, Egan, Regina K., Liu, Qingsong, Mironenko, Tatiana, Mitropoulos, Xeni, Richardson, Laura, Wang, Jinhua, Zhang, Tinghu, Moran, Sebastian, Sayols, Sergi, Soleimani, Maryam, Tamborero Noguera, David, López Bigas, Núria, Ross-Macdonald, Petra, Esteller, Manel, Gray, Nathanael S., Haber, Daniel A., Stratton, Michael R., Benes, Cyril H., Wessels, Lodewyk F. A., Saez-Rodriguez, Julia, McDermott, Ultan, Garnett, Mathew J.

المصدر: Articles publicats en revistes (Ciències Fisiològiques)

مصطلحات موضوعية: Càncer, Oncogènesi, Medicaments antineoplàstics, Resistència als medicaments, Farmacogenètica, Genomes, Fenotip, Cancer, Carcinogenesis, Antineoplastic agents, Drug resistance, Pharmacogenetics, Phenotype

وصف الملف: 15 p.; application/pdf

العلاقة: Reproducció del document publicat a: https://doi.org/10.1016/j.cell.2016.06.017Test; Cell, 2016, vol. 166, num. 3, p. 740-754; https://doi.org/10.1016/j.cell.2016.06.017Test; info:eu-repo/grantAgreement/EC/FP7/268626/EU//EPINORC; info:eu-repo/grantAgreement/EC/FP7/600388/EU//TECNIOSPRING; http://hdl.handle.net/2445/114504Test; 669922

الإتاحة: https://doi.org/10.1016/j.cell.2016.06.017Test
http://hdl.handle.net/2445/114504Test

المؤلفون: Howard Lightfoot, Thomas Cokelaer, Xeni Mitropoulos, Patricia Greninger, Lodewyk F. A. Wessels, Ultan McDermott, Daniel A. Haber, Daniel J. Vis, Xianming Deng, Michael Schubert, Sergi Sayols, Jinhua Wang, Heshani de Silva, Maryam Soleimani, Manel Esteller, Nanne Aben, Laura Richardson, Nuria Lopez-Bigas, Cyril H. Benes, Ewald van Dyk, Julio Saez-Rodriguez, Sebastian Moran, Emanuel Gonçalves, Regina K. Egan, Tinghu Zhang, Graham R. Bignell, Michael R. Stratton, Syd Barthorpe, Nathanael S. Gray, Han Chang, Petra Ross-Macdonald, Tatiana Mironenko, Michael P. Menden, Theo A. Knijnenburg, Qingsong Liu, Holger Heyn, David Tamborero, Mathew J. Garnett, Francesco Iorio

المساهمون: Universitat de Barcelona, European Molecular Biology Laboratory, Wellcome Trust Genome Campus, European Bioinformatics Institute, The Wellcome Trust Sanger Institute [Cambridge], Institute for Systems Biology [Seattle] (ISB), Netherlands Cancer Institute (NKI), Antoni van Leeuwenhoek Hospital, RWTH Aachen University, Delft University of Technology (TU Delft), Massachusetts General Hospital [Charlestown, MA, États-Unis], Bristol-Myers Squibb Research and Development (BMS), Bellvitge Biomedical Research Institute, Partenaires INRAE, Dana-Farber Cancer Institute [Boston], Harvard Medical School [Boston] (HMS), IMIM-Hospital del Mar, Generalitat de Catalunya, Institució Catalana de Recerca i Estudis Avançats (ICREA), University of Barcelona, Howard Hughes Medical Institute [Chevy Chase] (HHMI), Howard Hughes Medical Institute (HHMI), Cancer Genomics Netherlands [Rotterdam, The Netherlands], This work was funded by the Wellcome Trust (086375 and 102696). F.I. was supported by the European Bioinformatics Institute and Wellcome Trust Sanger Institute post-doctoral (ESPOD) program. T.A.K. was supported by the National Cancer Institute (U24CA143835) and the Netherlands Organization for Scientific Research. D.T. was supported by the People Programme (Marie Curie Actions) of the 7th Framework Programme of the European Union (FP7/2007-2013, 600388) and the Agency of Competitiveness for Companies of the Government of Catalonia (ACCIÓ). N.L.-B. was supported by La Fundació la Marató de TV3. M.E. was funded by the European Research Council (268626), the Ministerio de Ciencia e Innovacion (SAF2011-22803), the Institute of Health Carlos III (ISCIII) under the Integrated Project of Excellence (PIE13/00022), the Spanish Cancer Research Network (RD12/0036/0039), the Health and Science Departments of the Catalan Government Generalitat de Catalunya 2014-SGR 633, and the Cellex Foundation. U.M. was supported by a Cancer Research UK Clinician Scientist Fellowship. We thank Aiqing He for expression data and Ilya Shmulevich for assistance with the LOBICO framework. We thank P. Campbell, M. Ranzani, J. Brammeld, M. Petljak, F. Behan, C. Alsinet Armengol, H. Francies, V. Grinkevich, and A. 'Lilla' Mupo for useful comments. P.R.-M., H.C., and H.d.S. are employees and shareholders of Bristol-Myers Squibb. Research in the M.J.G. lab is supported in part with funding from AstraZeneca., European Project: 600388,EC:FP7:PEOPLE,FP7-PEOPLE-2012-COFUND,TECNIOSPRING(2013), European Project: 268626,EC:FP7:ERC,ERC-2010-AdG_20100317,EPINORC(2011), Rheinisch-Westfälische Technische Hochschule Aachen University (RWTH)

المصدر: Recercat. Dipósit de la Recerca de Catalunya
instname
Cell
Cell, Elsevier, 2016, 166 (3), pp.740-754. ⟨10.1016/j.cell.2016.06.017⟩
Dipòsit Digital de la UB
Universidad de Barcelona
Cell, 166(3)
Cell, 2016, 166 (3), pp.740-754. ⟨10.1016/j.cell.2016.06.017⟩
Cell 166(3), 740-754 (2016). doi:10.1016/j.cell.2016.06.017

مصطلحات موضوعية: 0301 basic medicine, MESH: Oncogenes, Carcinogenesis, [SDV]Life Sciences [q-bio], Gene Dosage, medicine.disease_cause, MESH: Gene Dosage, Medicaments antineoplàstics, MESH: DNA Methylation, Oncogènesi, Neoplasms, Antineoplastic agents, MESH: Neoplasms, MESH: Models, Genetic, Precision Medicine, Càncer, Càncer -- Aspectes genètics, Cancer, Genetics, Mutation, Phenotype, MESH: Drug Resistance, Neoplasm, 3. Good health, Fenotip, DNA methylation, Farmacogenètica, Càncer -- Tractament, Lineage (genetic), MESH: Mutation, MESH: Cell Line, Tumor, [SDV.CAN]Life Sciences [q-bio]/Cancer, Antineoplastic Agents, Biology, Gene dosage, MESH: Precision Medicine, General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, MESH: Analysis of Variance, Cell Line, Tumor, medicine, Humans, Genomes, Resistència als medicaments, Analysis of Variance, MESH: Humans, Models, Genetic, Biochemistry, Genetics and Molecular Biology(all), Oncogenes, DNA Methylation, medicine.disease, Precision medicine, Genòmica, 030104 developmental biology, Drug Resistance, Neoplasm, Pharmacogenetics, Pharmacogenomics, Drug resistance, MESH: Antineoplastic Agents

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48aedb67b996e2184441187799d05e4bTest
http://hdl.handle.net/2445/114504Test